Jump to content

Fasoracetam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jytdog (talk | contribs) at 23:12, 10 June 2017 (add). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fasoracetam
Names
IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one
Other names
(5R)-5-oxo-D-prolinepiperidinamide monohydrate, NS-105, AEVI-001, LAM 105, MDGN-001, NFC 1[1][2])
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
  • InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1 checkY
    Key: GOWRRBABHQUJMX-MRVPVSSYSA-N checkY
  • InChI=1/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
    Key: GOWRRBABHQUJMX-MRVPVSSYBL
  • O=C(N1CCCCC1)[C@@H]2NC(=O)CC2
Properties
C10H16N2O2
Molar mass 196.250 g·mol−1
Pharmacology
Oral
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Fasoracetam is a research chemical of the racetam family.[3] It is a nootropic, and has been in clinical trials for vascular dementia and attention deficit hyperactivity disorder.[2][4]

Fasoracetam appears to agonize all three metabotropic glutamate receptors and has improved cognitive function in rodent studies.[5] It is orally available and is excreted mostly unchanged via the urine.[6]

Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy.[5][7]

Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson identified fasoracetam's potential use in attention deficit hyperactivity disorder[5] and Hakonarson started a company called neuroFix Therapeutics, LLC to try to bring the drug market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.[7][8] neuroFix was acquired by Medigenics in 2015.[8] Medgenics changed its name to Aevi Genomic Medicine in 2016.[9] Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.[8]

References

  1. ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
  2. ^ a b "Drug Profile Fasoracetam".
  3. ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
  4. ^ "Recommended INN List 40" (PDF). WHO Drug Information. 12 (2). 1998.
  5. ^ a b c Connolly, J; Glessner, J; Kao, C; Elia, J; Hakonarson, H. "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder". Ther Innov Regul Sci. 49(5): 632–642. doi:10.1177/2168479015599811. PMC 4564067. PMID 26366330.
  6. ^ Malykh, AG; Sadaie, MR (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767.
  7. ^ a b Moskowitz, D. H. (2017). Finding the Genetic Cause and Therapy for Adhd, Autism and 22q: A Journey Into Precision Medicine That Could Affect Millions Worldwide. BookBaby (self published). ISBN 9781483590981.
  8. ^ a b c Sharma, B. "Medgenics: NFC-1 Could Be A Key Future Revenue Driver".
  9. ^ "Press Release: Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc". Aevi via MarketWired. 16 December 2016. {{cite web}}: Check |url= value (help)


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Fasoracetam&oldid=784975705"